EP1123306A4 - Inhibitors of platelet activation and recruitment - Google Patents

Inhibitors of platelet activation and recruitment

Info

Publication number
EP1123306A4
EP1123306A4 EP99951733A EP99951733A EP1123306A4 EP 1123306 A4 EP1123306 A4 EP 1123306A4 EP 99951733 A EP99951733 A EP 99951733A EP 99951733 A EP99951733 A EP 99951733A EP 1123306 A4 EP1123306 A4 EP 1123306A4
Authority
EP
European Patent Office
Prior art keywords
recruitment
inhibitors
platelet activation
platelet
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99951733A
Other languages
German (de)
French (fr)
Other versions
EP1123306A1 (en
Inventor
Charles R Maliszewski
Richard B Gayle Iii
Virginia L Price
Steven D Gimpel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of EP1123306A1 publication Critical patent/EP1123306A1/en
Publication of EP1123306A4 publication Critical patent/EP1123306A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
EP99951733A 1998-10-16 1999-10-13 Inhibitors of platelet activation and recruitment Withdrawn EP1123306A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10458598P 1998-10-16 1998-10-16
US104585P 1998-10-16
US10746698P 1998-11-06 1998-11-06
US107466P 1998-11-06
US14901099P 1999-08-13 1999-08-13
US149010P 1999-08-13
PCT/US1999/022955 WO2000023459A1 (en) 1998-10-16 1999-10-13 Inhibitors of platelet activation and recruitment

Publications (2)

Publication Number Publication Date
EP1123306A1 EP1123306A1 (en) 2001-08-16
EP1123306A4 true EP1123306A4 (en) 2002-07-03

Family

ID=27379766

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99951733A Withdrawn EP1123306A4 (en) 1998-10-16 1999-10-13 Inhibitors of platelet activation and recruitment

Country Status (7)

Country Link
EP (1) EP1123306A4 (en)
JP (1) JP2002527096A (en)
AU (2) AU6425699A (en)
CA (1) CA2345382A1 (en)
IL (1) IL142539A0 (en)
NZ (1) NZ511488A (en)
WO (2) WO2000023459A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264809B1 (en) 1998-10-16 2007-09-04 Immunex Corporation Methods of inhibiting platelet activation and recruitment
KR20010102978A (en) 1999-01-15 2001-11-17 아스트루 마이클 제이 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
GB9914326D0 (en) * 1999-06-18 1999-08-18 Rademacher Group Limited Materials and methods relating to the diagnosis and treatment of pre-eclampsia
WO2002014369A2 (en) * 2000-07-24 2002-02-21 Attenuon, Llc Human kininogen d5 domain polypeptides and their use
MY128992A (en) * 2000-08-25 2007-03-30 Merck Patent Gmbh Saratin for inhibiting platelet adhesion to collagen
WO2003052121A2 (en) * 2001-12-17 2003-06-26 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
EP1585817B1 (en) 2002-02-20 2009-09-02 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
SI1997512T1 (en) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Methods for treating TWEAK-related conditions
EP1545578A4 (en) 2002-08-28 2010-07-07 Immunex Corp Compositions and methods for treating cardiovascular disease
CA2498651C (en) 2002-09-13 2011-08-30 Universite Laval Nucleoside triphosphate diphosphohydrolase and uses thereof
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
EP2133430B1 (en) 2004-02-27 2014-12-17 APT Therapeutics, Inc. Design and therapeutic use of adpase enhanced apyrases
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
CN102441163A (en) * 2005-05-27 2012-05-09 比奥根艾迪克Ma公司 Tweak binding antibodies
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
DE102006046410A1 (en) * 2006-09-20 2008-03-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Medicaments for the prophylaxis or treatment or diagnosis of ischemic diseases
GB201522541D0 (en) * 2015-12-21 2016-02-03 Inst Research In Biomedicine Compositions
CN108203457B (en) * 2016-12-20 2022-09-06 山西医科大学 Antithrombotic small peptide omega KWR for targeted inhibition of platelet aggregation
EP3424957A1 (en) * 2017-07-03 2019-01-09 advanceCOR GmbH Fusion protein
UY38299A (en) 2018-07-18 2020-02-28 Novartis Ag SOLUBILIZED APIRASES, METHODS AND USES
WO2024023746A1 (en) * 2022-07-29 2024-02-01 Novartis Ag Improved production of cd39 variants

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416673A1 (en) * 1989-08-03 1991-03-13 Centro De Ingenieria Genetica Y Biotecnologia Method for the expression of heterologous proteins produced in fused form in E. coli, use thereof, expression vectors and recombinant strains
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
WO1996030532A1 (en) * 1995-03-24 1996-10-03 Novartis Ag Gene therapy for transplantation and inflammatory or thrombotic conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
AU5265296A (en) * 1995-04-10 1996-10-30 Universite De Sherbrooke Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416673A1 (en) * 1989-08-03 1991-03-13 Centro De Ingenieria Genetica Y Biotecnologia Method for the expression of heterologous proteins produced in fused form in E. coli, use thereof, expression vectors and recombinant strains
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
WO1996030532A1 (en) * 1995-03-24 1996-10-03 Novartis Ag Gene therapy for transplantation and inflammatory or thrombotic conditions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHADWICK B P ET AL: "The CD39-like gene family: identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from Drosophila melanogaster", GENOMICS,US,ACADEMIC PRESS, SAN DIEGO, vol. 50, no. 3, 15 June 1998 (1998-06-15), pages 357 - 367, XP002117226, ISSN: 0888-7543 *
CULLEN B. R.: "expression of a cloned human interleukin-2 cdna is emhanced by the substitution of a heterologous mrna leader region", DNA, vol. 7, no. 9, 1988, pages 645 - 650, XP000892169 *
MARCUS AARON J ET AL: "The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.", JOURNAL OF CLINICAL INVESTIGATION 1997, vol. 99, no. 6, 1997, pages 1351 - 1360, XP002136366, ISSN: 0021-9738 *
See also references of WO0023459A1 *

Also Published As

Publication number Publication date
JP2002527096A (en) 2002-08-27
NZ511488A (en) 2003-10-31
IL142539A0 (en) 2002-03-10
WO2000023094A2 (en) 2000-04-27
CA2345382A1 (en) 2000-04-27
AU772460B2 (en) 2004-04-29
EP1123306A1 (en) 2001-08-16
AU6411599A (en) 2000-05-08
WO2000023094A3 (en) 2000-07-27
AU6425699A (en) 2000-05-08
WO2000023459A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
IL142539A0 (en) Inhibitors of platelet activation and recruitment
IL128739A0 (en) Inhibition of blood platelet aggregation
IL127873A0 (en) Amidinoindoles amidinoazoles and analogs thereof as inhibitors of factor xa and of thrombin
EP1009415A4 (en) INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
HUP0104379A3 (en) New crystalline form of omeprazole and medicament containing it
PL328868A1 (en) Inhibitors of pharnesil protein transferase
EP1018987A4 (en) Neocartilage and methods of use
HUP0100366A3 (en) Homopolymers and copolymers of ethylene and applying them
GB9227026D0 (en) Dual inhibitors of no synthase and cycloosygenase
IL122813A0 (en) Thrombin inhibitors their preparation and use
PL341335A1 (en) Combination of ace and mmp inhibitors
GB9809869D0 (en) Inhibition of protein kinases
EP0806958A4 (en) Inhibition of platelet binding
PL334517A1 (en) Clavulate and one or more of exicipients containing granules
GB2345125B (en) Intumescent downlighter cover and method of manufacturing same
GB9930659D0 (en) Inhibitors of complement activation
EP0983958A4 (en) Treadboard device of man-conveyer and man-conveyer
ZA983065B (en) Inhibitors of protein farnesyltranferase
PL341222A1 (en) Substitute derivatives of isoquinoline and their application as anticonvulsants
PL342733A1 (en) Biocement of improved properties
EP1098659A4 (en) Libraries of polyhydroxamates and their analogs
HUP9800146A3 (en) Thalidomide-derivatives and use of them
EP1140121A4 (en) Cryogranulation of activated protein c
EP1140975A4 (en) Stable subtilin and methods of manufacture

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010516

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020522

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07H 21/02 A, 7A 61K 38/46 B, 7A 61K 38/46 J, 7A 61K 31:60 J

17Q First examination report despatched

Effective date: 20030528

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040821